StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

NovoCure pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

NovoCure's pe ratio was 734.3× on Mar 31, 2021.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2021Mar 31, 2021734.3×−176.4
2020Dec 31, 2020910.7×–

More NovoCure figures

See a number that looks wrong?